Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Docetaxel in Solid Tumors
NCT04827576Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of magrolimab in urothelial carcinoma (UC), small cell lung cancer (SCLC), sponsored by Gilead Sciences. Started Oct 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
urothelial carcinoma (UC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04827576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827576.